New drug cocktail targets myeloma tumors outside the bone marrow
NCT ID NCT06627751
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 28 patients with multiple myeloma that has returned or not responded to treatment and has spread to soft tissues or organs. The goal is to see if this combo can shrink tumors or keep the disease from getting worse. Participants will receive the drugs in cycles and be monitored for side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mezigdomide, carfilzomib, and dexamethasone
What this could lead to
If it works, this could offer a new treatment option for patients with multiple myeloma that has spread outside the bone marrow and is hard to treat.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drug combination may cause side effects like infections or heart issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact